|
|
|
29.03.26 - 07:18
|
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% (GlobeNewswire EN)
|
|
|
Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope, a key marker of kidney function, compared with placebo1. Fabhalta consistently outperformed placebo across key kidney outcomes over two years, demonstrating a slowing of disease progression and the potential to preserve kidney function in IgAN1.The results were published in the New England Journal of Medicine and simultaneously presented as late‑breaking data at the 2026 World Congress of Nephrology (WCN)....
|
|
|
28.03.26 - 20:03
|
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). Litifilimab is the first humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2), which has the potential to become the first innovative therapy approved for CLE in 70 years. Part A of AMETHYST evaluated the efficacy and safety of litifilimab through week 24, with reductions in skin disease activity reported across several measures. Results are consistent with the earlier positive Phase 2 LILAC study reported in The New England Journal of Medicine. Phase 2 results from LILAC and AMETHYST supported litifilimab's recently granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation. Results are being presented today at the American Academy of Dermatology (AAD) Annual Meeting....
|
|
|
|
|
|
|
|
|
|
|
28.03.26 - 17:21
|
Mulvihill Enhanced Split Preferred Share ETF Announces Year End Results (GlobeNewswire EN)
|
|
|
TORONTO, March 28, 2026 (GLOBE NEWSWIRE) -- (TSX: SPFD) Mulvihill Enhanced Split Preferred Share ETF (the “Fund”) (formerly Mulvihill U.S. Health Care Enhanced Yield ETF) announces results of operations for the year ended December 31, 2025. Increase in net assets attributable to holders of units amounted to $0.67 million or $0.31 per unit. As at December 31, 2025, net assets attributable to holders of units were $25.29 million or $9.36 per unit. Cash distributions to unitholders totaling $2.26 million or $1.00 per unit were paid during the year....
|
|
|
28.03.26 - 17:18
|
Premium Global Income Split Corp. Announces Year End Results (GlobeNewswire EN)
|
|
|
TORONTO, March 28, 2026 (GLOBE NEWSWIRE) -- (TSX: PGIC; PGIC.PR.A) (the “Fund”) announces results of operations for the year ended December 31, 2025. Increase in net assets attributable to holders of Class A shares amounted to $3.62 million or $1.32 per Class A share. As at December 31, 2025, net assets attributable to holders of Class A shares were $25.69 million or $6.77 per Class A share. Cash distributions of $0.75 per Preferred share and $0.96 per Class A share were paid during the year....
|
|
|
28.03.26 - 17:18
|
Mulvihill Premium Yield Fund Announces Year End Results (GlobeNewswire EN)
|
|
|
TORONTO, March 28, 2026 (GLOBE NEWSWIRE) -- (TSX: MPY) Mulvihill Premium Yield Fund (the “Fund”) announces results of operations for the year ended December 31, 2025. Increase in net assets attributable to holders of Class I units amounted to $1.29 million or $1.10 per Class I unit, increase in net assets attributable to holders of Class F units amounted to $1.25 million or $1.13 per Class F unit, increase in net assets attributable to holders of Class A units amounted to $0.40 million or $0.46 per Class A unit, and increase in net assets attributable to holders of ETF units amounted to $0.84 million or $0.55 per ETF unit. As at December 31, 2025, net assets attributable to holders of Class I were $12.67 million or $10.93 per Class I unit; net assets attributable to holders of Class F were $12.62 million or $10.94 per Class F unit, net assets attributable to holders of Class A units were $7.21 million or $10.08 per Class A unit, and net asset attributable to holders of ETF units were $15.32 mill...
|
|
|
28.03.26 - 17:00
|
Mulvihill Canadian Bank Enhanced Yield ETF Announces Year End Results (GlobeNewswire EN)
|
|
|
TORONTO, March 28, 2026 (GLOBE NEWSWIRE) -- (TSX: CBNK) Mulvihill Canadian Bank Enhanced Yield ETF (the “Fund”) announces results of operations for the year ended December 31, 2025. Increase in net assets attributable to holders of units amounted to $47.04 million or $3.75 per unit. As at December 31, 2025, net assets attributable to holders of units were $130.48 million or $11.86 per unit. Cash distributions to unitholders totaling $8.67 million or $0.70 per unit were paid during the year....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|